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Abstract: Ataxia is a neurodegenerative syndrome, which can emerge as a major element of a 
disease or represent a symptom of more complex multisystemic disorders. It comprises several 
forms with a highly variegated etiology, mainly united by motor, balance, and speech impairments 
and, at the tissue level, by cerebellar atrophy and Purkinje cells degeneration. For this reason, the 
contribution of astrocytes to this disease has been largely overlooked in the past. Nevertheless, in 
the last few decades, growing evidences are pointing to cerebellar astrocytes as crucial players not 
only in the progression but also in the onset of distinct forms of ataxia. Although the current 
knowledge on this topic is very fragmentary and ataxia type-specific, the present review will 
attempt to provide a comprehensive view of astrocytes’ involvement across the distinct forms of 
this pathology. Here, it will be highlighted how, through consecutive stage-specific mechanisms, 
astrocytes can lead to non-cell autonomous neurodegeneration and, consequently, to the behavioral 
impairments typical of this disease. In light of that, treating astrocytes to heal neurons will be 
discussed as a potential complementary therapeutic approach for ataxic patients, a crucial point 
provided the absence of conclusive treatments for this disease. 
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1. Introduction 
The role of the cerebellum in motor function is well recognized and results from an intricate 
circuitry through which this brain area gets connected with the basal ganglia and the cerebral cortex, 
as well as with peripheral motor and sensory pathways [1]. Malfunctions of any part of this circuitry 
result in imbalance and incoordination of posture and limbs, a disorder commonly known as ataxia 
and, specifically, as cerebellar ataxia in case of a cerebellar origin [2,3]. Nevertheless, besides motor 
alterations, ataxia has a very heterogeneous clinical presentation, comprising ocular impairments 
such as eye fixation deficits and nystagmus, and cognitive impairments with variable degrees of 
severity. This is due to the functional anatomy of the cerebellum, according to which distinct lobules 
in both the vermis and hemispheres are connected with distinct brain areas and are involved in 
diverse motor and non-motor functions [4]. Based on this functional anatomy, cerebellar ataxia is 
now clinically subdivided into (i) cerebellar motor syndrome, (ii) vestibulocerebellar syndrome, and 
iii) cerebellar cognitive affective syndrome [5]. 
The ataxia syndrome can either emerge as the major element of a disease course or represent a 
symptom of more complex multisystemic disorders, and it can have a highly variegated etiology: this 
makes the proper classification and correct diagnosis of ataxic patients very challenging. Namely, 
ataxic disorders can be classified, according to their etiology, in acquired, hereditary, or sporadic non-
hereditary degenerative forms, all comprising a huge list of diseases with distinct origins [3,6]. 
Acquired ataxias are due to exogenous or endogenous non-genetic causes, such as stroke, toxicity, 
vitamin deficiency, immune inflammation, nutritional deficiencies, and chronic central nervous 
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system (CNS) infections [6,7]. Hereditary forms comprise several genetic disorders that are 
characterized by slowly progressive incoordination of movement and speech and can be inherited (i) 
in an autosomal recessive manner, such as Friedreich’s ataxia (FA) and Ataxia Telangiectasia (AT); 
(ii) in a dominant manner, like Spinocerebellar Ataxia (SCA) and Episodic Ataxia (EA); or (iii) in an 
X-linked manner [8]. Finally, sporadic ataxia can either be caused by random mutations in single gene 
or comprise those forms for which a definite genetic impairment or acquired etiology cannot be 
found, such as the cerebellar variant of the Multiple System Atrophy (MSA) [9] and the so-called 
sporadic adult-onset ataxia of unknown etiology (SAOA) [10].  
Common features of most ataxias are cerebellar atrophy and Purkinje cells (PCs) degeneration. 
For this reason, despite back in the past gliosis was repeatedly reported in autopsies of human ataxic 
samples [11–13], researchers have focused for many years mainly on neuronal dysfunctions, largely 
overlooking the possible implication of non-neuronal cells, including microglia, oligodendrocytes, 
and astrocytes, in this disorder. Nevertheless, in the past years, this trend changed its direction. 
Indeed, early microglial activation was reported during post-mortem analyses in several forms and 
animal models of ataxia and was described to play a detrimental role by driving neuroinflammation 
[14]. Moreover, white matter degeneration was reported in SCA2,3,7,10 and AT [15–21] and often 
correlated with ataxia severity: although white matter changes have largely been suspected to be 
secondary to neuronal loss, they are also likely to result from oligodendrocytes impairments. Indeed, 
mutant ATXN3 expression was shown to cause cell-autonomous transcriptional changes in 
oligodendrocytes that may directly disrupt white matter and be, therefore, implicated in the 
pathogenesis of SCA3 [16]. Similar changes in oligodendrocyte genes transcription may also occur in 
other genetic forms of ataxia and, in general, may cause oligodendrocyte dysfunctions that could 
impede the correct propagation of neuronal action potentials and, in turn, promote neuronal 
dysfunction and degeneration. Along the same line, in MSA, alpha-synuclein expression in 
oligodendrocytes was suggested to perturb their ability to provide trophic support to neurons, 
thereby contributing to diffuse neurodegeneration in this disease [22]. Lastly, an increased number 
of oligodendrocytes without mitotic activity was observed in childhood ataxia with diffuse central 
hypomyelination (CACH) syndrome, again suggesting that defects in these cells may be implicated 
in the etiopathology of cerebellar dysfunctions [23]. 
Among glial cells, astrocytes play a plethora of roles essential for brain development, 
homeostasis, and function [24–26]. As a consequence, no wonder they are increasingly being 
described as implicated in several neurodevelopmental and neurodegenerative disorders, such as 
Rett syndrome, fragile X mental retardation, amyotrophic lateral sclerosis, and Alzheimer’s disease 
[27–29], and they may be similarly involved in the pathophysiology of ataxia. 
In the cerebellum, astrocytes are generated through a tightly regulated process and can be 
classified according to their morphologies and layering into three main categories, comprising 
Bergmann glia (BG) and granular layer astrocytes in the cerebellar cortex and fibrous astrocytes in 
the cerebellar white matter [30,31]. In the cortical layers, different astrocyte types interact with 
distinct neuronal subsets (Figure 1) and, therefore, are likely to develop neuron-specific functional 
properties, similarly important for the correct cerebellar development and functioning. Nevertheless, 
provided their highly specialized morphology and tight connection with the whole dendritic tree and 
soma of PCs, BGs are the most extensively studied astrocytes in the cerebellum, and their functions 
in supporting cerebellar development, PC synaptogenesis, and synaptic activity have already been 
described [32]. On the other side, very little is known about the specific functions and physiology of 
astrocytes in the granular layer, although their close relationship with the cerebellar glomeruli (i.e., 
the synaptic structures composed of mossy fibers rosettes, Golgi neuron boutons, and granule cells 
“GC” dendrites) [33,34] suggest that they may be similarly crucial for the regulation of tissue 
homeostasis and cerebellar circuits functioning. 
In the last few decades, growing evidences are pointed at cerebellar astrocytes, specifically BG, 
as leading characters of a non-cell-autonomous neuronal degeneration in distinct forms of ataxia. 
Although intense work is still needed to clarify the role of astrocytes other than BG in this pathology, 
and despite the available knowledge is still very fragmentary and mainly ataxia type-specific, the 
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present review will attempt to provide a comprehensive view of the mechanisms through which 
these cells are involved in the pathophysiology of ataxias, depicting a potential temporal cascade of 
events that eventually lead to the non-cell-autonomous neurodegeneration typical of this disease. A 
specific attention will be given to the pitfalls of the available models to study astrocytes’ contribution 
to the pathology, to promising new approaches to address this issue in the future and, importantly, 
to the potential forthcoming benefits of new therapies that specifically target astrocytes’ dysfunctions, 
a crucial point provided the absence of conclusive treatments for this disease.  
 
Figure 1. Schematic picture showing cerebellar cytoarchitecture. Cerebellar cortex is composed of 
three layers. In the innermost layer, the Granule cell layer, excitatory granule cells are surrounded by 
Golgi and Lugaro cells, two kinds of inhibitory interneurons, as well as by the excitatory unipolar 
brush cells and velate astrocytes. Here, velate astrocytes are in close relationship with the so-called 
cerebellar glomeruli, composed of mossy fibers rosettes, Golgi neuron boutons, and granule cells 
dendrites. The Purkinje cell layers host the cell bodies of Purkinje cells and Bergmann glia, whose 
dendrites and fibers, respectively, span the whole length of the outermost layer of the cerebellum, the 
Molecular layer. Here, granule cells’ parallel fibers synapse directly onto Purkinje cells dendrites and 
have contact points with molecular layer interneurons, called Basket and Stellate cells. Moreover, the 
processes of Bergmann glia are in tight connection with the whole dendritic tree and soma of Purkinje 
cells. In the cerebellar white matter, fibrous astrocytes are aligned to axons, while in the deep 
cerebellum the cerebellar nuclei neurons receive inputs from both Purkinje cells and climbing fibers 
of inferior olive neurons and project either back to the inferior olive (the GABAergic neurons) or to 
the brainstem, midbrain, and thalamus (the glutamatergic neurons). Arrow, projections coming from 
outside the cerebellum. 
2. Astrocytes Impairments are often Associated to Ataxic-Like Symptoms and Ataxia 
A first hint of the possible involvement of astrocytes in ataxia is the evidence that their deficiency 
at multiple levels, from developmental impairments to the lack of their functional support to neurons, 
often results in motor impairments (Table 1). Indeed, astrocytes ablation from either the developing 
or the adult murine brain through distinct approaches was observed to result in severe ataxia, 
associated with PCs ectopic layering and abnormal dendritic arborization and with the degeneration 
of GCs [35,36]. These results provided the first in vivo evidence that astrocytes are critical for both 
cerebellar development and neuronal survival in the adult mouse brain. Along the same line, not 
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only the lack of BG specification from cerebellar radial glia, due to the manipulation of several distinct 
genes, resulted in abnormal foliation and lamination and in locomotion defects [37–40] but also the 
incorrect maintenance of the BG phenotype (i.e., their ectopic location in the molecular layer and/or 
acquisition of a stellate morphology) during late postnatal development caused signs of ataxia in 
diverse mouse models [41,42]. Further, morphological defects of BG radial processes in vimentin-null 
mice also translated into impaired motor coordination, likely due to an aberrant structural and 
homeostatic support on PCs [43]. At last, the acquisition of an immature- or reactive-like state by 
cerebellar astrocytes in Dicer-deficient mice, as revealed by alterations in their transcriptome profiles, 
was shown to precede and to be likely responsible for a rapid neurologic decline, characterized by 
ataxia, GCs apoptosis and PCs degeneration [44]. Interestingly, this non-cell-autonomous 
neurodegeneration was faster in the central and posterior zones of the cerebellum and slower in the 
anterior and nodular areas, thereby suggesting a diverse susceptibility of neurons to astrocytes 
dysfunctions or an intrinsic heterogeneity of astrocytes in their response to ataxia-related mutant 
gene expression. 
Evidence showing that cerebellar astrocytes may be involved in the pathophysiology of ataxia 
also came from the study of distinct animal models of this and other pathologies. Reactive 
astrocytosis and BG proliferation were indeed associated with PCs degeneration in the first mouse 
model of SCA1 (a polyglutamine spinocerebellar ataxia due to the expansion of a CAG trinucleotide 
repeat in the ATXN1 gene), in which the human mutant gene was expressed under the control of a 
PC-specific promoter [45]. On the other side, BG appeared to decrease before PCs degeneration in a 
different, non-PC-specific, mouse model of the same disease [46]. Moreover, the first three weeks of 
postnatal development were reported to be a critical period for the mutant ATXN1 gene expression 
to permanently influence the symptoms observed in the adult [31,47]. It is interesting to note that this 
developmental stage corresponds to the peak of astrocytes proliferation and differentiation, thereby 
suggesting that altered astrocytes development due to mutant ATXN1 expression may significantly 
contribute to disease progression. Increased expression of the glial fibrillary acidic protein (GFAP), 
astrogliosis, and thickening of BG processes were also observed in regions with extensive PC loss in 
a PC-specific Tmem30a KO mouse model that displays early-onset ataxia. In this case, astrocytic 
reactivity resulted from neuronal impairments and/or degeneration and likely further exacerbated 
neuronal loss contributing to disease progression, as will be discussed later [48]. A prominent 
astroglial activation and an impaired functioning of the glutamate-aspartate transporter GLAST, 
mediated by the proinflammatory cytokine interleukin-1β (IL-1β), were observed in the cerebella of 
experimental autoimmune encephalomyelitis (EAE) mice. These data hint that cerebellar astrocytes 
may also be involved in the cerebellar deficits and motor impairments typical of Multiple Sclerosis 
[49]. 
Interestingly, cerebellar astrocytes are also likely to be involved in the pathogenesis of those 
acquired ataxias due to alcohol abuse. Indeed, they were shown in vitro to be capable of synthesizing 
high levels of retinoic acid (RA) when exposed to ethanol [50]. RA, ligand for a group of ligand-
activated transcription factors known as the RA receptors, is necessary for the development of many 
organs including the CNS but, when too much concentrated, can have teratogenic effects. Specifically, 
RA exposure was shown to cause abnormalities similar to those observed in the fetal alcohol 
syndrome (FAS), many of which are associated with cerebellar deficits: the aforementioned evidence 
thereby suggests that the cerebellar pathology exerted by ethanol may occur, at least in part, through 
an increased production of RA by cerebellar astrocytes. Although a direct in vivo demonstration of 
this hypothesis is still missing, the same authors showed that cerebellar RA levels were increased also 
in rat pups after ethanol administration [50]. Besides the dramatic effects of ethanol exposure on 
cerebellar development, alcohol abuse in adult life also causes cerebellar dysfunctions [51]. In this 
frame, astrocytes are again likely to play a crucial role. Indeed, even a brief ethanol exposure was 
shown to be sufficient to cause long-lasting changes in the gene expression, proliferation, and activity 
of mature astrocytes of distinct brain regions, with dramatic effects on the surrounding neurons [52]. 
Overall, these results indicate that astrocytes may contribute to cerebellar dysfunctions resulting from 
alcohol exposure both during fetal/postnatal and adult life. 
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Table 1. Astrocytes developmental or functional deficiencies result in neuronal degeneration and/or 
motor impairments.  
Astrocytes 
Alterations 
Animal Model 
Applied 
Cellular and 
Histological 
Impairments 
Behavioral 
Impairments Reference 
Astrocytes ablated 
postnatally 
 
Herpes simplex 
virus- thymidine 
kinase expressed in 
mice under the 
control of the hGFAP 
gene promoter 
 
Disordered 
radial glia; 
PCs ectopically 
distributed; 
abnormal PCs 
dendritic trees, 
depletion of GCs; 
reduction in 
cerebellar size; 
disruption of the 
cellular layers 
Severe ataxia [35] 
Astrocytes ablated in 
the adult  
 
Targeted E. 
coli nitroreductase 
expression to the 
astrocytes of 
transgenic mice with 
the GFAP promoter 
 
Abnormal PCs 
dendrites; GCs 
degeneration 
Ataxic behavior [36] 
Absence of 
functional BG 
 
Overexpression of 
the group C protein 
Sox4 in transgenic 
mice under the 
control of the hGFAP 
promoter 
 
Fissures were not 
formed; neuronal 
layering was 
dramatically 
disturbed 
Ataxic behavior [37] 
Disorganization of 
BG population 
 
Knockout mouse 
with inactivation of 
the gene coding for 
the ubiquitin ligase 
Huwe1 in cerebellar 
GC precursors and 
radial glia 
 
GCs migration 
defects; ectopic 
GC clusters; 
layering 
aberrations  
Postnatal 
lethality 
[38] 
Radial glia fail to 
transform into BG 
 
Deletion of Ptpn11 
gene in the entire 
mouse cerebellum  
 
Disorganized 
lamination and 
absence of 
cerebellar folia 
Ataxic behavior [39] 
Deficits in BG 
specification 
 
Mouse model lacking 
Zeb2 in cerebellar 
radial glia 
 
Compromised 
inward 
migration of 
GCs, cortical 
lamination 
dysgenesis 
Ataxic behavior [40] 
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Ectopic positioning 
and aberrant stellate 
phenotype of BG 
arising postnatally  
 
 
Conditional 
knockout mice in 
which the APC gene 
is inactivated in 
GFAP-expressing 
cells 
Loss of PCs and 
cerebellar 
atrophy 
Ataxic behavior [41] 
 
Decreased numbers, 
ectopic positioning 
and aberrant stellate 
phenotype of BG 
arising postnatally 
 
Conditional Sox2 
ablation in the whole 
mouse cerebellum or 
astrocytes 
Cerebellar 
vermis 
hypoplasia, 
abnormal 
glutamate 
transport  
Ataxic behavior  [42] 
 
BG abnormal 
development 
 
Vimentin knock-out 
mice 
Abnormal PCs 
dendrites; PCs 
degeneration 
Ataxic behavior [43] 
Immature/reactive-
like phenotype 
acquisition by 
astrocytes  
Cre-loxP conditional 
deletion of Dicer 
selectively from 
postnatal astroglia in 
mice 
Cerebellar 
degeneration, 
apoptosis of GCs, 
degeneration of 
PCs 
 
Ataxic behavior, 
seizures, 
uncontrollable 
movements and 
premature death 
arising late 
postnatally 
 
[44] 
BG, Bergmann glia; GC, granule cells; hGFAP, human Glial Fibrillary Acidic Protein, PCs, Purkinje cells. 
3. Astrocytes Involvement in Ataxia as Revealed by Astrocyte-Specific Mutant Animal Models 
In light of the aforementioned evidence and of those implying astrocytes as involved in the 
pathogenesis of several neurologic disorders, over the last fifteen years, scientists have begun to shift 
gradually their focus from neurons to astrocytes in the investigation of the cellular mechanisms 
underlying ataxia. Due to the genetic nature of many forms of this disease, the creation of animal 
models in which the mutant genes were selectively expressed or deleted in glial cells or, specifically, 
in astrocytes has been the most common approach to tackle this issue. 
A first example is represented by SCAs that mostly belong to the category of polyglutamine 
diseases and comprise distinct forms characterized by CAG expansions on specific genes. The glial 
expression of SCA-related polyglutamine proteins has been shown several times to cause non-cell 
autonomous neurological symptoms, pointing to glial cells as anything but passive bystanders in the 
pathogenesis of this disease. Drosophila models expressing in glial cells the mutant ATXN1 and 
ATXN3 genes, associated with SCA1 and SCA3, respectively, showed accumulation of the protein 
fragments in glial intranuclear inclusions, accompanied by progressive degeneration of glial and 
neuronal cells, severe behavioral defects, and lethality [53,54]. Similar pieces of evidence of non-cell 
autonomous neurodegeneration were also obtained in a SCA7 mouse model where the expression of 
the mutant ATXN7 gene in all cells but not in PCs led to ataxia and PCs degeneration [55]. 
Nevertheless, the demonstration that astrocytes were the main actors in this process only came some 
years later, when the conditional expression in BG of the mutant gene through a Gfa2 promoter 
(version of the GFAP promoter with restricted expression in BG) was sufficient to cause motor 
incoordination and PCs pathology [56]. Later, the same authors developed an elegant animal model 
to better investigate the contribution of BG to the disease pathogenesis, by removing the mutant gene, 
in a context of ubiquitous expression, in a temporally and cell type-regulated fashion. Although the 
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deletion of the mutant ATXN7 gene solely in BG was not sufficient per se to prevent the development 
of ataxia and neurodegeneration, its excision from BG in combination with PCs and inferior olivary 
(IO) neurons yielded a synergistic effect on the delay of symptoms onset [57]. Altogether, these results 
support a significant role of BG in SCA7 pathogenesis where both cell-autonomous and non-cell 
autonomous mechanisms are likely to contribute to neurodegeneration in a tightly interconnected 
network between neurons and BG. Similarly, neurodegeneration in SCA17 was reported to depend 
on the concomitant expression of the mutant TATA-binding protein (TBP) gene in both neurons and 
astrocytes, while the mutant gene expressed in either of the two cell populations only caused a mild 
PCs degeneration [58]. A synergistic effect of defective neurons and astrocytes holds true also for 
other forms of ataxia, as addressed later in this review. 
Another genetic form of ataxia is Friedreich ataxia (FA), caused by an unstable GAA expansion 
in the first intron of the FXN gene, which results in decreased levels of a protein called frataxin. To 
mimic frataxin deficiency, animal models were developed in which the wild-type FXN gene was 
ubiquitously silenced, resulting in neuronal degeneration, motor impairments, and reduced lifespan. 
Interestingly, specific deletion of this gene in glial cells in Drosophila generated FA-like symptoms 
comparable to those of the whole-body knockout flies [59], and its ablation in developing mice from 
GFAP-expressing neuronal and astrocyte precursors resulted in severe ataxia and early death, 
associated with growth and survival impairments in cerebellar astrocytes [60]. Although, in this 
mouse model, the contribution of mutant neuronal and astrocyte precursors could not be 
discriminated, the evidence that the alterations observed were specific for cerebellar astrocytes and 
absent in forebrain astrocytes suggests that a greater vulnerability of developing cerebellar astrocytes 
to frataxin depletion may contribute to the highly specific cerebellar disturbances typical of FA. On 
the other side, in one of the very few studies exploiting cultured human astrocytes, cortical astrocytes 
with frataxin deficiency (obtained through an shRNA knockdown approach) also showed 
detrimental effects, with signs of reduced proliferation and survival. This hints that the cerebellar-
specific phenotype of this disease may also result from minor sensitivity to frataxin-deficient 
astrocytes of some neuronal populations in regions other than the cerebellum [61]. 
Ataxia Telangiectasia is a rare inherited disorder caused by mutations in the Ataxia Telangiectasia 
Mutated (ATM) gene, coding for the homonym protein involved in cell division and DNA repair. The 
first evidence of a glial-mediated non-cell autonomous mechanism of neurodegeneration in AT came 
from the specific ATM knockdown in glial cells in Drosophila, shown to be sufficient to activate an 
inflammatory response mediated by glial cells that drove the degeneration of both neurons and glia 
and resulted in reduced mobility and decreased lifespan [62]. Nevertheless, the aberrant effects of 
ATM deficiency in mouse cerebellar astrocytes were unveiled with an in vitro chimeric system and 
confirmed in vivo only very recently [63]. Indeed, while chimeric cultures composed of normal 
astrocytes and ATM-deficient neurons did not show any structural or functional anomalies, ATM-
deficient astrocytes co-cultured with normal neurons not only showed a reduced length and number 
of processes but also led to altered numbers of pre- and postsynaptic puncta, to impaired neuronal 
synchronization, and to significant neuronal death. Adult cerebella from ATM-depleted mice 
similarly showed a disrupted morphology of both BG and GL astrocytes, with increased expression 
of synaptic markers at GABAergic synapses [63]. Although the neuronal population in the chimeric 
primary cultures was mostly represented by GCs and therefore no evidences are available on the 
effect of ATM-deficient astrocytes on PCs, on the whole, these results suggest that the 
neurodegeneration and impaired network dynamics in AT may at least in part due to a 
malfunctioning of cerebellar astrocytes, resulting in aberrant structural connections among neurons. 
Niemann–Pick disease type C (NPC) is a rare autosomal recessive multisystemic disorder with 
early-onset ataxia as a cardinal feature, due to a progressive loss of cerebellar PCs [64]. The gene 
underlying 95% of the cases of this disorder is NPC1, involved in late endosomal lipid sorting and 
trafficking and, therefore, exploited as the main target for mutations or deletion in animal models 
intended to mimic this pathology. The available evidences on the role of glial cells and/or astrocytes 
in the coordination problems and progressive cerebellar degeneration typical of NPC have been 
controversial but eventually pointed to astrocytes as crucial contributors to this disease. Exploiting a 
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chimeric mouse model with functional NPC1 only in some cells with a mosaic-like pattern, Ko and 
colleagues [65] first concluded that degeneration of PCs was cell-autonomous, similarly to Lopez et 
al. [66] who, some years later, observed that NPC1 rescue solely in astrocytes was not capable of 
preventing neurodegeneration and motor incoordination in NPC1-null mice. Nevertheless, these 
evidences have some points of criticism and are not sufficient at all to rule out astrocytes’ contribution 
to NPC pathology. Indeed, provided the tight connection of individual PCs with up to eight BG, in a 
mosaic context the lack of rescue of mutant neurons by some surrounding wild type astrocytes and, 
vice versa, the absence of detrimental effects exerted by some mutant astrocytes on healthy PCs [65] 
may be due to compensatory effects by other mutant or normal astrocytes, respectively. To clarify 
this point, animal models in which the NPC1 gene is conditionally mutated in all astrocytes are 
needed. On the other side, although NPC1 reintroduction in neurons of NPC1-deficient mice 
prevented neuron degeneration, this resulted in an only temporarily improved motor coordination, 
eventually not sufficient to block disease progression and mouse death [66]. Although the authors 
did not comment on this, this temporary rescue is likely to be due to surrounding mutant astrocytes 
that eventually contribute to the progression of the ataxic phenotype. Along this line, if neither 
astrocyte- nor neuron-specific NPC1 rescues are per se sufficient for an efficient recovery, it is likely 
that both neurons and astrocytes are involved in the pathogenesis of this disease. Indeed, an 
analogous study, in which the astrocyte-targeted re-expression of NPC1 in NPC1-null mice was 
obtained through a GFAP promoter-driven transgene, reported an enhanced survival of mice, 
decreased astrocytes reactivity, and delayed degeneration of PCs [67], thereby indicating that 
astrocytes contribute to disease progression. The same authors successively confirmed the co-
operation of dysfunctional astrocytes and neurons in NPC by re-expressing the normal gene in both 
cell types, that translated into a nearly normal phenotype with neurodegeneration, motor symptoms, 
and death all delayed of several months compared to the neuron-only re-expression [68]. 
Further positive evidences came also from in vitro studies. First, in mouse neuron–astrocyte 
cocultures, NPC1-null astrocytes were shown to cause a decreased neurite growth of wild-type 
neurons due to a reduced estradiol release [69]. Moreover, simultaneous absence of the gene in co-
cultured neurons and glial cells, but not in neurons solely, resulted in impaired presynaptic 
development, as revealed by reduced synaptophysin-positive puncta on PC dendrites [70]. Although 
it is not clear whether this altered presynaptic input on PCs may contribute to the progressive 
degeneration of these cells and the behavioral impairments typical of NPC, these results indicate that 
both neuronal and glial NPC1 are required for proper presynaptic development and, added to the 
previous observations, confirm that neurons and astrocytes may cooperate in NPC disease 
progression. To further confirm this point, the investigation of the in vivo effects of an astrocyte-
and/or neuron-specific deletion of the gene is still missing and is needed in future studies. 
Overall, these results confirm that the complex interplay between neurons and astrocytes is 
necessary for the proper development and functioning of the cerebellar circuitries; at least in genetic 
forms of ataxias, where astrocyte-specific contribution was so far investigated, impairments in 
neurons and astrocytes both contribute to disease progression. Some of the mechanisms underlying 
this process have already been clarified and will be hereafter addressed. 
4. How do Astrocytes Contribute to Ataxias? A Multi-Step Hypothesis 
4.1. Cell-Autonomous Effects of Mutant Gene Expression in Astrocytes 
Mutant ataxia-related genes are ubiquitously expressed and, therefore, are unlikely to cause 
developmental and/or functional impairments in neurons solely. Rather, their expression in 
astrocytes is likely to act as a first hit with distinct pathogenetic ripple effects. 
As a first example, in a human astrocyte cell culture model of SCA7, the mutant ATXN7 gene 
was shown to downregulate the expression of RELN, gene intimately involved in the development 
and maintenance of the whole cerebellum and, specifically, of PCs [71]. Its downregulation in mutant 
SCA7 astrocytes was suggested to cause a non-cell autonomous, astrocytes-mediated, selective 
degeneration of PCS, thereby likely explaining the tissue specificity of SCA7. Nevertheless, these 
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results still need to be confirmed in vivo in both the developing and mature cerebellum. Similarly, a 
SCA1 mouse model allowed to identify MAXER, coding for a novel multiple α-helix protein located 
at endoplasmic reticulum (ER), as an ATXN1 target gene. MAXER reduction in BG was shown to 
mediate their functional deficiency, inhibiting their proliferation, and reducing GLAST expression. 
The reduced levels of GLAST, both due to a decreased total number of BG and to a reduced 
expression on the spared cells, in turn, translated in glutamate-mediated neurotoxicity on PCs that 
could be rescued by MAXER overexpression [46]. Reduced numbers of BG, due to their massive 
death, were also very recently described in a SCA28 mouse model, in which the mutated gene 
AFG3L2 was selectively expressed in astrocytes [72]. Here, BG death was only the endpoint of a 
progressive degenerative process, characterized by their ectopic position, aberrant morphology, 
decreased expression of the calcium-binding protein S100 and the glutamate transporter GLT-1, 
upregulation of GFAP, abnormal mitochondrial network, and activated metabolic stress response. 
Altogether, these alterations may result in the lack of metabolic support on PCs, in glutamate-
mediated PCs excitotoxicity and in the acquisition of a “reactive” phenotype by BG, and may, 
therefore, not only magnify but even cause PCs degeneration in SCA28. The acquisition of a reactive 
phenotype by astrocytes following their expression of mutant genes is indeed a common feature of 
distinct forms of ataxia. In the first humanized ATXN3 knock-in mouse model (Ki91 mice), expression 
of the mutant ATXN3 in astrocytes was reported to cause astrogliosis in the cerebellar white matter 
(one of the hallmarks of SCA3 in humans) due to the expression of Serpina3n [73]. Interestingly, 
Serpina3n expression was evident already in newborn mice, long before the onset of PCs degeneration 
and behavioral deficits in motor coordination, that appeared much later in one-year-old cerebella. 
Similarly, activated inflammatory pathways such as NF-kB were uncovered in mutant astrocytes in 
a cell culture model of SCA17 and their blocking was shown to ameliorate neurodegeneration [58]. 
Altogether, these evidences indicate that the expression of mutant ataxia-related genes in 
astrocytes may act as an intrinsic factor that, in turn, causes their developmental and/or functional 
impairments and ultimately contributes, or causes, degeneration of the nearby neurons. 
One of the first and most common impairments appears to be the acquisition of a reactive 
phenotype by astrocytes whose detrimental effects in distinct forms of ataxia will be addressed in the 
next section. 
4.2. Astrogliosis: An Early Point Of No Return? 
Cerebellar astrogliosis is not only among the first cell-intrinsic effects of the expression of ataxia-
related genes in cerebellar astrocytes [58,72,73] but it is also probably one of the astrocytes’ earliest 
responses to the abnormal behaviors of mutant neurons. 
Early astrocyte activation was indeed observed in both the cerebellar nuclei (CN) and cortex in 
a SCA21 mouse model in which the mutated gene TMEM240 was expressed only in neurons [74]. 
Here, neuronal lysosomal impairments likely led to an active release of Damage-associated molecular 
patterns (DAMPs) or other factors that in turn triggered astrogliosis, resulting in motor dysfunctions 
without signs of neurodegeneration. Similarly, cerebellar astroglia was reported in several SCA1 
mouse models to exhibit early signs of reactivity, recognized through increased GFAP expression, 
hypertrophy of cell bodies and processes, and expression of pro-inflammatory mediators [75]. 
Interestingly, this occurred well before the first signs of neurodegeneration and motor impairments 
and correlated with the disease in a spatio-temporal pattern, with most of the activated cells found 
in the most severely affected cerebellar regions. Again, this astrocyte activation was not caused by 
neurodegeneration, rather, it was shown to be triggered by signals originating from mutant PCs and 
could be arrested by preventing neuronal expression of the mutant ATXN1 gene. Successively, the 
same authors demonstrated that cerebellar astrogliosis contributes to SCA1 in a biphasic manner. By 
modulating astrocytes reactivity through the inhibition of the astroglial NF-κB (nuclear factor kappa-
light-chain-enhancer of activated B cells) signaling, they showed that when this pathway was 
inhibited during an early stage of disease (i.e., before the onset of motor deficits), the disease severity 
was exacerbated, whereas its inhibition during a later phase ameliorated the motor impairments 
without, however, saving PCs from death [76]. These results are suggestive of the first 
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neuroprotective role played by astrocytes in SCA1 pathogenesis, which becomes harmful later on. 
Very recently, an early increase in the expression of brain-derived neurotrophic factor (BDNF) was 
identified as a key mediator of the initial neuroprotective role of astrocytes: an early delivery of this 
factor is indeed capable of delaying motor impairments and PCs pathology in a SCA1 mouse model 
[77]. Whether a biphasic role of astrogliosis in the disease onset also holds true for other kinds of 
ataxia is still needs to be elucidated. 
The crucial role of astrogliosis in the pathogenesis of ataxia has been recently further 
demonstrated in conditional mouse models of cerebellar neuroinflammation, where the IκB kinase 2 
(IKK2), activator of the NF-κB pathway, was expressed in astrocytes or selectively in BG [78]. IKK2 
expression for a limited time was indeed sufficient to cause neuroinflammation, astrogliosis, and 
subsequent ataxic features due to selective degeneration of PCs. On the other side, the inactivation of 
Myd88, a crucial factor for the activation of the IKK/NF-κB pathway, was shown to mitigate 
neuroinflammation and PCs death in a SCA6 mouse model [79]. 
Overall, these evidences demonstrated that astrocytes’ activation, induced either cell- or non-
cell-autonomously, can exacerbate or even cause neuronal dysfunctions, which in turn trigger a 
further amplification of astrogliosis in a detrimental vicious circle. This astrogliosis-like astrocytes 
activation was shown to be irreversible in some instances [78], determining a very early and time-
restricted “point of no return” that points to early intervention as a crucial approach for the 
development of new therapeutic strategies. Importantly, this pathogenetic mechanism is likely to be 
crucial not only for the genetic forms of ataxia so far described but also for the inflammatory 
cerebellar ataxias, occurring in various autoimmune/inflammatory conditions in which inflammatory 
insults cause selective cerebellar neurodegeneration. 
4.3. Astrogliosis Detrimental Effects on the Surrounding Neurons 
After brain injury, astrocytes were reported to undergo a dramatic morphological and 
transcriptional transformation and acquire two possible reactive phenotypes, named “A1” and “A2” 
based on their inductive cue and effects on neurons and other surrounding cells [80,81]. Specifically, 
while A2 astrocytes are induced by ischemia and strongly promote neuronal survival and tissue 
repair by secreting neurotrophic factors, A1 are induced after acute brain injury by microglia and, by 
secreting neurotoxins, are lethal to both neurons and oligodendrocytes. Moreover, A1 astrocytes fail 
in promoting neuronal survival, synapse formation, and function, and are unable to phagocyte 
synapses and myelin debris. These impaired mechanisms all result in neurodegeneration and often 
contribute to disease progression [82]. Although a direct evidence that reactive astrocytes in 
cerebellar ataxia acquire an A1 phenotype is still missing, several impairments were described to 
occur in these cells that may cause non-cell-autonomous neurodegenerative effects. These 
impairments, which will be addressed hereafter, comprise a deficient glutamate uptake, the loss of 
structural and functional support for neurons, and the production of toxic substances or their 
impaired clearance from the extracellular space. 
4.3.1. Neurotoxicity Caused by Impaired Glutamate Uptake 
One of the main consequences of the morphological changes in reactive astrocytes is an altered 
allocation of GLAST, astrocytic glutamate transporter necessary to maintain extracellular glutamate 
concentrations and avoid neuronal excitotoxicity. GLAST mispositioning may either be due to its 
spatial redistribution following astrogliosis, like its cluster-like appearance reported to occur in a 
SCA1 transgenic mouse model [83] or from the activation-related retraction of astrocytes processes, 
both resulting in its dislocation from PCs synapses. Furthermore, astrogliosis induced by the 
activation in astrocytes of IKK2, enzymatic complex involved in propagating the cellular response to 
inflammation, resulted in a strong downregulation of both GLAST and GLT-1, indicating that IKK2 
per se may be a negative regulator of their expression in vivo and may directly mediate the local 
imbalance of glutamate homeostasis and neuronal excitotoxicity, at least in inflammatory cerebellar 
ataxias [78]. A progressive loss of GLAST was also reported in a mouse model of SCA5, leading to 
PCs degeneration and the worsening of the ataxic phenotype [84]. Here, PCs death was the result of 
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a synergistic loss first of the neuronal glutamate transporter Excitatory amino-acid transporter 4 
(EAAT4) in PCs and then of GLAST in astrocytes, with PCs in the posterior cerebellum showing a 
higher susceptibility due to the differential patterns of expression of EAAT4 across parasagittal bands 
[85,86]. Although the molecular mechanisms leading to the progressive loss of GLAST in these mice 
still need to be elucidated, it is tempting to speculate that this may result from the induction of an 
astrocyte reactive phenotype by surrounding sick PCs. 
The significant contribution of glutamate-associated pathways to the pathogenesis of ataxia was 
very recently confirmed through innovative disease models based on SCA2 or SCA3 patients-derived 
induced pluripotent stem cells (iPSCs) [87]. Indeed, the treatment of iPSCs-derived neurons with 
glutamate resulted in altered composition of glutamate receptors, intracellular Ca2+ imbalance and, 
eventually, cytotoxicity and degeneration. 
It is important to note that, besides resulting from astrocytes reactivity, impairments in 
glutamate uptake may also be caused by cell-autonomous mechanisms. Indeed, the ablation in mice 
of the SLC1A3 gene, coding for the GLAST transporter, results in severe motor impairments and 
several missense mutations, either inherited or de novo, in the GLAST gene were shown to cause 
distinct forms of episodic ataxia (EA), whose symptoms severity appeared sometimes correlated with 
the extent of glutamate transporter dysfunction (Table 2) [88–93]. Moreover, reduced expressions of 
GLAST and/or GLT-1 were reported in models of SCA1, SCA7, and SCA28 in which the mutant genes 
were selectively expressed in astrocytes [46,56,72], indicating that the genetic alterations underlying 
some forms of ataxia may directly interfere with the astrocytes-mediated glutamate uptake. 
Interestingly, a defective expression of GLT-1 in BG, associated with PCs hyperexcitation and 
motor impairments, was also reported in a mouse model of myotonic dystrophy type 1 (DM1), a 
multisystemic disorder in which cerebellar abnormalities are implicated [94]. This evidence suggests 
that an imbalance in glutamate uptake by cerebellar astrocytes may also contribute to a broad 
spectrum of disorders in which the cerebellum is involved through the altered motor and/or non-
motor functions. 
Table 2. Mutations in the SLC1A3 (Solute Carrier Family 1 Member 3) gene cause episodic ataxia 6 (EA6). 
Distinct missense mutations, either inherited or sporadic, were identified in the SLC1A3 gene in 
patients with EA. This syndrome was designated as episodic ataxia 6 (EA6), although it shared many 
overlapping clinical features with EA2, identified by the presence of heterozygous pathogenic 
variants in the CACNA1A (calcium voltage-gated channel subunit alpha1) gene.  
Mutation in The 
SLC1A3 Gene 
Functional 
Implications 
Clinical Features Family 
History 
Reference 
Heterozygous de 
novo Pro290Arg 
missense 
mutation 
 
Decreased expression 
of GLAST and 
reduced capacity of 
glutamate uptake; 
increased anion 
currents through 
GLAST 
 
Episodic and progressive 
ataxia, seizures, alternating 
hemiplegia, and migraine 
headache 
 
Sporadic [89,95] 
 
Cys186Ser 
missense 
mutation 
Modest but significant 
reduction of 
glutamate uptake 
 
Milder manifestations of 
EA without seizures or 
alternating hemiplegia; 
overall similar to EA2 
 
+ [90] 
Heterozygous 
Val393Ile 
missense 
mutation 
May influence 
glutamate binding 
and anion 
conductance 
 
EA2 like symptoms; 
recurrent ataxia, slurred 
speech, interictal 
+ [91] 
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nystagmus with late-onset 
age of sixth decade 
 
Arg454Gln 
(Arg499Gln) 
missense 
mutation 
n.a. 
 
Progressive ataxia, 
dysarthria, dysphagia, in 
some cases with adult-
onset 
 
+ [96] 
Missense 
Ala329Thr 
mutation 
(concomitant 
with a mutation 
in the CACNA1A 
gene) 
 
n.a. 
Ataxia, dizziness, gaze-
evoked nystagmus, 
seizures 
+ [92] 
De novo 
Thr318Ala 
missense 
mutation 
 
n.a. 
 
Typical EA2-like 
symptoms: recurrent 
ataxia, slurred speech; 
interictal nystagmus, mild 
cognitive impairment. 
Late-onset in the fourth or 
sixth decades 
 
Sporadic [92] 
De novo 
Met128Arg 
missense 
mutation 
May perturb the 
hydrophobic status of 
the membrane and 
affect glutamate 
uptake 
 
Repeated episodes of 
ataxia: truncal ataxia, 
intentional tremor, slurred 
speech 
 
Sporadic [93] 
+, presence of family history; EA, episodic ataxia, GLAST, glutamate/aspartate transporter; n.a., not available. 
4.3.2. Neurotoxicity Caused by S100beta Release 
Another mechanism through which reactive astrocytes contribute to PCs degeneration is the 
production and release of toxic substances, and the calcium-binding protein S100B turned out to be 
one of them. Indeed, the presence in PCs of S100B-containing vacuoles, well before the onset of motor 
impairments, was reported in a SCA1 mouse model [97] and was later on traced back to autophagic 
mechanisms and associated with alterations in the morphology of PCs dendritic spines [98]. The same 
authors further demonstrated, both in vitro and in vivo, that the presence of S100B-loaded vacuoles 
in PCs correlated with the absence of ATXN1 nuclear inclusions, thereby suggesting that glial S100B 
may modulate the solubility of the mutant ATXN1 protein and, in turn, mediate its toxicity in PCs 
[99]. Although the underlying signaling pathways are still not fully known, the authors speculated 
that the sustained supply of S100B by reactive astrocytes may activate in PCs some factors, such as 
the NDR2 kinase, which destabilize BG-PC contact sites and neurite growth and result in PCs 
degeneration. Moreover, S100B Ca2+-chelating properties may modulate sodium channels in neurons 
and cause their Ca2+ overload, contributing to both aberrant synaptic transmission and neurotoxicity 
[100,101]. It is also worth noting that an excessive extracellular content of S100B was reported to cause 
alterations in BG cortical organization and morphology, thereby further contributing to the 
weakening of PC-BG contacts and the redistribution of glutamate transporters, in another, 
detrimental, vicious circle [100]. 
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Importantly, elevated S100B concentrations were found in the serum of SCA3 patients, although 
uncorrelated to the disease duration or severity [102]. These results suggest that S100B overload may 
be a common pathogenetic mechanism of distinct forms of ataxia and, importantly, point to the 
application of this protein as a peripheral marker of disease in ataxia. 
Overall, these evidences indicate that much more than a neuronal issue lags behind 
neurodegeneration in ataxias. Conversely, astrocytes actively participate in the neurodegenerative 
process, causing and/or exacerbating neuronal dysfunctions. Although most of the pathogenetic 
mechanisms described above can derive from cell-autonomous astrocytes dysfunctions and 
individually contribute to disease onset or progression, here a temporal cascade of events was 
proposed in which astrocytes are active and crucial players in distinct phases of the ataxia course 
(Figure 2). If true, this multi-step hypothesis of astrocytes involvement in ataxia should be taken into 
account in view of developing new astrocytes-targeted and, ideally, stage-specific therapeutic 
approaches, as will be discussed later. 
 
Figure 2. The multi-step hypothesis of astrocytes’ involvement in ataxia. Astrocytes contribute to 
neuronal degeneration and motor impairments in distinct phases of the disease course. The 
expression of ataxia-related mutant genes in astrocytes can cause cell-autonomous impairments (A) 
that can contribute to neurodegeneration either directly (H) or indirectly through the acquisition of a 
reactive phenotype (B). This was demonstrated to occur in distinct in vitro models, and, in vivo, in 
BG, while whether this happens also in the other cerebellar cortical astrocytes still needs to be 
clarified. Astrocytes’ reactivity can also result from neuronal impairments (C; demonstrated for PCs, 
likely to occur also in GCs), through the release from damaged neurons of DAMPs and other factors 
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that can activate IκB kinase (IKK)/NF-kB inflammatory pathways in astrocytes that, in turn, become 
reactive (B). Interestingly, astrocytes’ reactivity was shown to play a dual function in Spinocerebellar 
Ataxia (SCA1) progression, first beneficial and later detrimental. Whether this holds true also for other 
forms of ataxia still needs to be elucidated. Reactive astrocytes, in turn, trigger neurodegeneration 
through distinct mechanisms, like the impairment of glutamate uptake (D) and the release of the 
calcium-binding protein S100B (E). Other neurotoxic mechanisms were shown to be an increase in the 
chloride efflux from astrocytes (F) and their accumulation of stress responses (G). Both these 
mechanisms were described to result from cell-autonomous impairments in astrocytes but may also 
result indirectly from their acquisition of a reactive phenotype. Glu, Glutamate, Big red arrows, 
successive step; small arrows, increase (facing up) or decrease (facing down). White question mark, 
hypothetical successive step; red question mark, hypothetical cellular involvement.  
5. Other Pathogenetic Mechanisms of Astrocytes Involvement in Ataxia 
5.1. Well beyond Glutamate Uptake: The Role Of Glast As Ion Channel And Its Implication In The 
Pathogenesis Of Ataxia 
Besides the mechanisms so far described, which may be involved at distinct levels in a putatively 
multi-step progression of the disease, another way in which astrocytes have been recently associated 
to the pathogenesis of ataxia is through an abnormal anion conductance of GLAST that, although 
mostly known for glutamate transport, also plays an ancillary function as a chloride channel [103] 
(Figure 2). Specifically, the episodic ataxia 6 (EA6)-related point mutation P290R in the SLC1A3 gene 
(encoding GLAST) was shown not only to reduce the number of GLAST transporters on the surface 
of mammalian cells and impair their glutamate uptake but also to cause the appearance of larger 
anion currents with or without the administration of external glutamate [95]. Moreover, this mutation 
caused episodic paralysis of Drosophila larvae when expressed in glial cells [104]. A very similar 
behavior, with paralysis and astroglial aberrant morphologies, was induced after the expression in 
Drosophila of a chloride-extruding K+-Cl− cotransporter and was rescued by the expression of a Na+-
K+-Cl− cotransporter, which normally allows chloride to enter into cells [104]. These results suggested 
for the first time that, although a reduced glutamate uptake was thought the be the main 
pathophysiological process underlying episodic ataxia, the P290R mutation in the SLC1A3 gene also 
causes abnormal chloride flow from astrocytes, contributing in this way to disease progression. These 
evidences were indeed very recently confirmed by the development of a transgenic mouse line, in 
which the mutation was carried by GLAST-expressing astrocytes solely (Slc1a3P290R/+ mice). This 
animal model was shown to suffer from epilepsy, ataxia, and showed cerebellar atrophy, thereby 
closely resembling the features of EA6 [105]. Specifically, these degenerative effects were unveiled to 
be triggered by an increased chloride efflux from BG, resulting in BG apoptosis and, subsequently, 
in a secondary loss of glutamate clearance and cerebellar atrophy. 
The maintenance of a certain chloride concentration inside BG and, likely, inside astrocytes in 
general appears, therefore, to be a crucial point that had been so far underestimated. Not only 
chloride efflux from astrocytes may reduce their volume and dislocate their processes from synapses 
but it may also cause their death, therefore impairing their supportive role in neuronal functions and 
survival. Moreover, a reduced astrocytic chloride concentration may increase the driving force for 
GABA uptake of those transporters on astrocytes that cotransport both GABA and chloride, therefore 
attenuating GABA-mediated synaptic transmission. 
Astrocytes were shown in the past to actively accumulate chloride upon activation. It will be 
fascinating to clarify whether any kind of alteration in chloride homeostasis may result also from the 
acquisition of a reactive phenotype by astrocytes in ataxia, and be therefore part of the multi-step 
progression of the disease proposed in the previous section. Similarly, whether an impaired GLAST 
chloride conductance is also involved in ataxias other than EA6 still needs to be elucidated. 
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5.2. When Astrocytes “Burn Out”: Stressed Astrocytes Cause Accumulation Of Oxidative Stress And 
Neurodegeneration 
The role of astrocytes as antioxidant supporters for neurons is well accepted [106–108], and the 
loss of this support was often shown to lead to neuronal death in diverse neurodegenerative diseases 
[109,110]. Oxidative stress, associated with the activation of both mitochondrial and endoplasmic 
reticulum (ER) stress responses in astrocytes, was indeed shown to be involved in the 
pathophysiology of distinct ataxias (Figure 2). 
First, in distinct in vitro models of Ataxia Telangiectasia, ATM-deficient astrocytes were shown 
to activate their oxidative and ER stress responses, which in turn translated in a senescence-like 
growth arrest through multiple Extracellular signal-regulated kinases 1/2 (ERK1/2)-dependent 
mechanisms, as demonstrated by the fact that treatments with the antioxidant N-acetyl-L-cysteine 
(NAC) not only restored their defective proliferation but also suppressed ERK 
phosphorylation/activation [111–113]. Stressed and senescent astrocytes, in turn, failed in providing 
their antioxidant support on neurons that eventually degenerated. Recently, the mechanism 
underlying this suboptimal antioxidant support of astrocytes was found in their impaired ability to 
import l-cystine and produce reduced glutathione (GSH), which is normally secreted by healthy 
astroglia in response to oxidative stress to provide additional support to neurons [114]. Specifically, 
stressed cerebellar astrocytes isolated from ATM-mutant mice showed decreased expression of the 
cystine/glutamate exchanger subunit xCT and of GSH reductase, which translated into reduced levels 
of both intracellular and secreted GSH. Consequently, when co-cultured with healthy neurons, these 
astrocytes provided insufficient GSH levels to support neuronal survival [114]. Nevertheless, the 
absence of neurodegeneration in AT experimental models did not allow so far to clarify whether this 
mechanism also holds true for astrocytes in vivo. 
A similar involvement of oxidative stress in neurodegeneration was also proposed for Friedreich 
ataxia, in light of the abnormal levels of antioxidant enzymes found in the cerebella of frataxin-
depleted mice [60]. In a Drosophila model of this disease, the expression of the mutant frataxin 
protein in glial cells was indeed shown to increase lipid peroxidation, inducing mitochondrial 
dysfunction and, in turn, accumulation of fatty acids and cell degeneration, which translated in a 
shortened lifespan and impaired locomotor performances [59]. Interestingly, co-expression in the glia 
of frataxin-deficient flies of Glaz, one of the Drosophila homologs of apolipoprotein D (ApoD), was 
sufficient to increase the lifespan and improve locomotor activity, likely due to its modulation of lipid 
composition and oxidation. The same authors later demonstrated that also an enhanced iron 
transport inside mitochondria was involved in the degenerative phenotype induced by frataxin 
depletion, as demonstrated by the fact that a reduction of mitoferrin, a mitochondrial iron 
transporter, significantly improved the motor impairments, while its overexpression enhanced them 
[115]. Further, Loria and colleagues [61] reported that frataxin-depleted cultured human astrocytes 
had altered mitochondrial morphology and suffered great oxidative stress, therefore supporting the 
idea that an increased mitochondrial iron content favors astrocytes oxidative stress. 
Besides mitochondrial dysfunction, endoplasmic reticulum (ER) stress was recently reported as 
a novel and crucial player in the progression and etiology of FA. Indeed, in a Drosophila model of 
this disease, the downregulation in glial cells of Marf, a protein known to play crucial roles in 
mitochondrial fusion, mitochondrial degradation, and in the interface between ER and mitochondria, 
improved motor functions, neuronal degeneration, and lipid homeostasis through the suppression 
of ER stress [116]. Very similar results were obtained through ER stress reduction by means of two 
different chemical compounds, allowing the authors to conclude that the advantages conferred by 
Marf downregulation in glia were mainly due to its role in the mitochondrial-ER tethering. 
Overall, these evidences support the role of astrocytes in both AT and FA, which is mediated by 
a progressive accumulation of either mitochondrial or ER stress, or both. Stressed astrocytes, in turn, 
fail to support and protect from oxidative stress their surrounding neurons, which eventually 
degenerate. Besides that, the analysis of the secretome from cultured human frataxin-deficient 
astrocytes also supported the hypothesis that stressed astrocytes may directly mediate 
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neuroinflammation and, in turn, neurodegeneration through the release of specific cytokines 
involved in these processes [61]. 
6. Treating Astrocytes to Heal Neurons: New Promising Approaches For Ataxia Therapy 
Provided the complex and extremely heterogeneous scenario of ataxias, no curative and 
confirmed pharmacological treatments are still available, neither for those forms with unknown 
etiology nor for those whose causes have already been clarified. The available treatments are 
supposed to ease symptoms and overall improve the quality of life of ataxia patients, comprising (i) 
physical and speech therapies to mitigate tremors, stiffness, and speech problems, (ii) globulines 
injections to boost the immune system in case of immune-mediated ataxias, and (iii) counseling or 
medications to alleviate the associated depression, anxiety, and sleep disorders. The only exceptions 
are played by those ataxias caused by nutritional deficiencies, such as a lack of vitamin E or coenzyme 
Q10, which respond well to supplements, and by some subtypes of episodic ataxia, which can often 
be successfully treated with the drug Acetazolamide, a carbonic anhydrase inhibitor supposed to 
prevent ataxic attacks by normalizing regional pH in the cerebellum and, in turn, by inducing 
physiologic changes in several types of ion channels [117]. In view of developing new therapies aimed 
at eradicating the disease from its roots, it is reasonable to think that targeting astrocytes’ 
dysfunctions, besides neuronal impairments, maybe a very promising approach, provided their 
critical involvement in the onset and/or progression of this disease. These putative astrocyte-targeted 
treatments should strictly depend on the nature of the disease and, ideally, should be stage-specific, 
provided the variegated mechanisms through which astrocytes have been reported to be involved in 
distinct forms and phases of ataxia. 
The beneficial effects of treatments limiting astrocytes impairments were reported in distinct 
ataxia animal models and, in some instances, also in ataxic patients. As an example, treatments with 
estradiol were shown to delay the onset of neurological symptoms and increase PCs survival in 
Niemann Pick disease, counteracting its decreased secretion by NPC1-deficient astrocytes [69]. 
Similarly, in SCA7 patients, treatment with the histone deacetylase inhibitor trichostatin A could, at 
least in part, restore the defective reelin transcription in mutant astrocytes, promoting the 
accumulation of the mutant ATXN7 protein into nuclear inclusions and, therefore, slowing disease 
progression by reducing PCs neurotoxicity [71]. 
Inflammation and astrogliosis also appear as crucial players in disease progression. In this 
context, anti-inflammatory astroglia-based therapeutic approaches have been proposed for both 
SCA1 and SCA17 [58,76]. Yet, the evidence that intracerebroventricular injections of IL-1 receptor 
antagonist (IL-1ra) in EAE mice reduced motor deficits are very promising in view of responsiveness 
to anti-inflammatory treatments also in other forms of ataxia [49]. Importantly, although a bi-phasic 
role of astrogliosis in ataxia pathophysiology has been so far suggested only for SCA1, these 
treatments may need to consider the stage of disease progression to achieve therapeutic efficacy. In 
a first phase of the disease, when astrocytes’ reactivity may be protective [76], the inhibition of 
astroglial NF-κB signaling, likely effective at later stages [58], may indeed result detrimental, while 
BDNF delivery may delay disease onset fostering astrocytes’ defensive role against neurotoxicity, at 
least in SCA1 [77]. Similarly, even stimulating BG/astrocytes proliferation at this stage could be a 
viable therapeutic intervention [118]. 
The release of S100B by reactive astrocytes is one of the mechanisms through which these cells 
mediate the non-cell autonomous neurodegeneration of the surrounding PCs. In this context, the 
construction of substances that attenuate the activity of myo-inositol monophosphatase 1 (IMPA1), 
target of S100B whose activation is involved in the spines and dendrites abnormalities in PCs, has 
been suggested as potential therapeutic approach for SCA1 [98]. Similarly, treatment with the S100B 
inhibitory peptide TRTK12 was shown to improve motor performances in a model of SCA1 [99]. 
Importantly, both the activity of myo-inositol and the presence of S100B were proposed as glial-based 
biomarkers that could serve as indicators of disease progression and severity [75]. 
Besides S100B secretion, the impairment in glutamate uptake is the other main mechanism 
through which astrocytes contribute to neuronal toxicity and death. In this frame, in a mouse model 
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of SCA28, increased expression of the glutamate receptor EAAT2 in astrocytes, promoting glutamate 
clearance, was obtained with the administration of the antibiotic ceftriaxone and ameliorated the 
ataxic phenotype [119]. Similarly, the cerebellar phenotype of myotonic dystrophy mice, due to 
spontaneous hyperactivity of PCs resulting in motor incoordination, was also ameliorated by 
ceftriaxone treatment [94], thereby suggesting that this kind of approach may be beneficial in distinct 
ataxic patients. Along the same line, anti-glutamate drugs were shown to reduce the death of SCA2- 
and SCA3-iPSCs-derived neurons [87], further indicating that glutamate-associated pathways are 
very promising drug targets across the variegated spectrum of ataxias. 
Antioxidant therapies likely represent another valid approach to effectively ameliorate at least 
AT and FA, by reducing oxidative stress and supporting astrocytes’ functions in neuronal survival. 
Indeed, in AT in vitro models, NAC treatments were able not only to suppress the activation of stress 
and senescence pathways in mutant astrocytes [112] but also to restore normal GSH levels by 
circumventing the defects in l-cystine import in these cells, which were, therefore, again capable of 
supporting neuronal survival and neurite outgrowth [114]. Another approach to normalize GSH 
levels and overcome neuronal death in AT may be the drug-induced activation of the 
cystine/glutamate exchanger subunit xCT, already suggested for Parkinson’s disease and 
amyotrophic lateral sclerosis [120,121]. This kind of therapy would be, however, highly problematic, 
since it could result in overaccumulation of glutamate in the extracellular space causing neuronal 
toxicity. The direct delivery of NAC or other cysteine precursors, therefore, likely represents the 
safest solution among the antioxidant approaches. Along the same line, apolipoprotein D may 
provide an important therapeutic target, due to its modulation of lipid composition and lipid 
oxidation, as hinted by evidences obtained in a Drosophila model of FA [59]. On the other side, 
counteracting iron transport inside mitochondria may be another promising option to slow down 
neuronal degeneration in FA, and this could be achieved through mitoferrin depletion or iron 
chelation therapies [115,122]. Last, insulin-like growth factor I (IGF-I) injections were shown to 
protect neurons from frataxin deficiency in a non-cell autonomous fashion, both enhancing frataxin 
levels in astrocytes and potentiating their neuroprotective properties through the stimulation of the 
Akt/mTOR pathway [123]. 
Of particular relevance, gene therapy in the shape of antisense oligonucleotides (ASO) has been 
recently shown to attenuate the disease in a SCA3 mouse model by targeting not only neurons but 
also astrocytes [124]. Along the same line, a novel kind of synthetic antisense long non-coding RNAs 
capable of upregulating the expression of specific genes of interest, called SINEUPS, has been very 
recently shown to rescue defective frataxin expression and activity in a human cellular model of 
Friedreich’s Ataxia [125]: it will be interesting to evaluate in the future whether this approach can 
target both neuronal and non-neuronal cells. Gene therapy undoubtedly represents the new frontier 
for genetic diseases, and the precise targeting of cells of interest without side effects is one of the main 
goals of this innovative therapeutic approach: in view of its application in the genetic forms of ataxia, 
these cellular targets should be not only neurons but also astrocytes. 
Importantly, in case cerebellar astrocytes are healthy because not primarily affected in ataxia 
etiology, they are likely to take a crucial part in the so-called “cerebellar reserve”[126]. The cerebellar 
reserve is indeed defined as the capacity of the cerebellum to compensate and restore function in 
response to pathology, and cerebellar astrocytes, with their endogenous neuroprotective effects, are 
likely to counteract neuronal damage and loss as described to occur in several other kinds of brain 
injury. This aspect is particularly relevant in view of planning new treatment strategies that could 
boost the astrocytes’ neuroprotective activity, at least in the initial phase of the disease when they 
maintain their structural and functional integrity. Astrocytes were indeed described to be able to (i) 
remove the excessive glutamate released by damaged or dying neurons and, therefore, protect other 
cells from excitotoxicity and neurodegeneration; (ii) take damaged mitochondria up from sick 
neurons defending them against mitochondrial dysfunctions; (iii) help attracting robust 
inflammation to sites of tissue damage in order to neutralize pathogens, clear debris, and promote 
tissue repair; iv) express high levels of GSH in response to oxidative stress, which often results from 
an overproduction of reactive oxygen species (ROS) following injury [127]. These same mechanisms 
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are likely to occur also in ataxia. Indeed, astrocytes astrogliosis was proposed to be neuroprotective 
in the first phases of SCA1 [76] and distinct treatments boosting specific astrocytes’ neuroprotective 
mechanisms were described to ameliorate the cerebellar phenotype of distinct forms of ataxia. 
Among them, the aforementioned drugs targeting glutamate-associated pathways may be beneficial 
in ataxic patients not only by counteracting astrocytes’ impairment in glutamate uptake but also by 
supporting healthy astrocytes in their neuroprotective activity. Similarly, the antioxidant therapies 
described before may facilitate astrocytes’ response to oxidative stress. Besides their neuroprotective 
effects, cerebellar astrocytes are likely to contribute to the “cerebellar reserve” also by sustaining 
compensatory responses in neural circuits, restoring lost connectivity in dysfunctional cerebellar 
networks. This was indeed described to occur in chimeric culture models of AT in which both 
structural and functional anomalies of ATM-deficient neurons were completely rescued by the 
presence of healthy astrocytes [63]. Moreover, in the wake of the recent evidence indicating that 
differentiated astrocytes can be triggered to change their fate and reprogram into neurons in the 
injured mouse cerebral cortex [128], if properly boosted, cerebellar astrocytes may represent a very 
promising source of new neurons in ataxic contexts, thereby incrementing the cerebellar reserve. This 
may be true specifically for BG. Indeed, evidence suggests that they belong to the same lineage of 
PCs, with whom they share the same origin in the embryonic ventricular zone and partially 
overlapping developmental trajectories [31]. Moreover, BG postnatal progenitors share striking 
similarities, both under the molecular and morphological point of view, with the embryonic outer 
radial glia (oRG) responsible for the generation of the majority of cortical neurons, are capable in vitro 
of producing neurospheres, and were shown to be capable of reprogramming into granule cells (GCs) 
following a postnatal depletion of GC precursors [129]. For these reasons, BG may represent a novel 
and abundant stem cell population in the adult cerebellum and appear to be the best cerebellar 
candidates to be triggered toward the PC fate, particularly promising in view treating cerebellar 
disorders. 
7. Conclusions and Future Perspectives 
The evidences summarized here indicate that astrocytes play pivotal roles in the pathogenesis 
of ataxias. Specifically, although the available knowledge is still fragmentary and mostly disease-
specific, it looks evident that numerous mechanisms of astrocytes involvement in neurodegeneration 
are shared by diverse forms of ataxias and likely contribute to disease progression in a phase-specific 
fashion, of particular relevance in view of developing new astrocytes-targeted therapeutic 
approaches. Nevertheless, most of this knowledge relies on experimental models that mostly fail to 
faithfully recapitulate the human disease. For instance, the available animal models for AT do not 
show robust neurodegeneration or cerebellar atrophy, hallmarks of the human disease [130], while a 
mouse model of SCA1 in which the mutant ATXN1 was expressed at the endogenous level only 
showed mild behavioral impairments [46]. Similarly, an insufficient reduction of frataxin in FA 
mouse models translated into the absence of anomalies in motor coordination [60,131,132]. These 
effects, partially due to the short lifespan of mice that does not allow the neurons to accumulate 
significant damage, were often overcome by creating new animal models with transgenes expression 
exceeding the endogenous levels, which in turn led to dramatic and exaggerated outcomes that again 
did not reflect reality [56,133]. Importantly, in view of unveiling the astrocyte-specific effects of 
mutant protein expression/deletion, conditional experimental lines were developed in which, 
however, the transgene induction was often not sufficiently robust and, most importantly, depended 
on the kind of promoter and system (i.e., Cre-loxP, Tet-On/Off) used [60]. Lastly, many studies 
addressing glial involvement in ataxia [53,59,62,104,115,116] have been, still recently, based on the 
Drosophila model that, although very suitable to this aim due to its limited number of glial cells with 
well-known positions and molecular markers, may lead to an oversimplification of this issue. To 
overcome all these limitations, the use of patient-derived iPSCs differentiated into astrocytes or in 
the form of three-dimensional organoids, or of diseased human glial chimeric mice will represent, in 
the next future, a very promising approach to draw more solid conclusions on the cellular and 
molecular mechanisms underlying astrocytes involvement in ataxias and to screen drugs for 
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treatments, as done for many other neurodegenerative disorders [134,135]. Moreover, the future 
identification of molecular markers specific for the distinct cerebellar astrocyte phenotypes, hopefully 
possible thanks to high throughput -omic approaches, will allow not only to differentiate distinct 
astrocyte subtypes from patient-derived cells but also to isolate distinct astrocytes populations from 
the available animal models and to develop new conditional ones in view of elucidating, if any, the 
role of cerebellar astrocytes other than BG in ataxia pathophysiology. 
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